2-year YOSEMITE and RHINE results show faricimab reduces treatment burden in patients with DMO

Dr Jennifer I. Lim reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular oedema.

Emily Kaiser, editor of Modern Retina™, sits down with Dr Jennifer I. Lim to discuss her ARVO 2022 presentation, “Efficacy, durability, and safety of faricimab in diabetic macular oedema: 2-year results from the phase 3 YOSEMITE and RHINE trials.” YOSEMITE and RHINE trials had previously shown noninferiority between faricimab and aflibercept for the treatment of diabetic macular oedema (DMO), and the 2-year results showed that up to 60% of patients could be dosed with faricimab every 16 weeks and 70% of patients could be dosed every 12 weeks following 4 loading doses.